Stories
Updates: Lilly's Global COVID-19 Response
View Story
Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization
View Story
Time to Tear Down the Rebate Wall
View Story
When the World Called for Help with COVID-19, We Were Ready
View Story
Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody
View Story
An Update on Lilly’s Commitment to Quality Manufacturing
View Story
CEO Dave Ricks Shares Lilly's Principles of COVID-19 Antibody Therapy Pricing and Access
View Story
Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
View Story
Increasing Diversity in Clinical Trials
View Story
Overcoming Barriers to Biomarker Testing in Cancer
View Story